At the EHA conference in Amsterdam we are joined by Professor Theodoros P Vassilakopoulos to discuss the most exciting new developments in standards of care for Hodgkin lymphoma.
1. What are the limitations of current standards of care for Hodgkin lymphoma (HL)? (0:05)
2. What is the role of brentuximab vedotin in the current treatment paradigm for HL? (2:10)
3. How is the role of brentuximab vedotin likely to further evolve in the treatment of HL? (3:33)
4. How can immune checkpoint inhibitors best fit into the treatment paradigm for HL? (4:45)
5. What emerging therapeutic options seem most promising in the future treatment of HL? (5.30)
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
Share this Video
Related Videos In Lymphoma
ZUMA-23 study of axicabtagene ciloleucel as first-line therapy in large B-cell lymphoma: Jason Westin, EHA 2023
ZUMA-23 (NCT05605899) is an on-going phase 3 study investigating axicabtagene ciloleucel (axi-cel) CAR T cell therapy as a first-line therapy in patients with high-risk large B-cell lymphoma. touchONCOLOGY caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss what previous clinical trials have taught us about […]
Axicabtagene ciloleucel for the treatment of large B-cell lymphoma: Jason Westin, EHA 2023
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved to treat patients with relapsed/refractory large B-cell lymphoma. We caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss the current treatment paradigm for large B-cell lymphoma, the limitations of current […]
Jennifer Brown, ASH 2022: Zanubrutinib for patients with relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma, ALPINE (phase III) results
The ALPINE study in patients with relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma has shown that zanubrutinib may offer potential advantages over ibrutinib. In this touchONCOLOGY interview, we speak with Dr Jennifer Brown (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss the mechanism of action of zanubrutinib, its potential advantages over ibrutinib and the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!